BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, May 8, 2026
Home » Authors » Omar Ford

Articles by Omar Ford

SEMDA 2015: TriNet's Goldfield looking for vision, technology when making acquisitions

April 2, 2015
By Omar Ford

SEMDA 2015: Data, regulatory hurdles dominate first day of SEMDA conference

April 1, 2015
By Omar Ford

AAOS 2015: Syncera changes paradigm of orthopedic sales model

March 31, 2015
By Omar Ford

LAS VEGAS — Just across from Smith & Nephew's (S&N; London) 90X100 makeshift office on the exhibit floor at the American Academy of Orthopedic Surgeons (Rosemont, Illinois) annual meeting – lies Syncera (Mansfield, Massachusetts), a business unit set to change the model of how orthopedic products are sold.


Read More

AAOS 2015: Cayenne Medical releases 2-year results of Mirror Partial Knee study

March 30, 2015
By Omar Ford

AAOS 2015 conference: Value over volume is the new shift in treating patients

March 30, 2015
By Omar Ford

LAS VEGAS — Reimbursement. Physician pay. Value over volume. All are words that were pretty common at the American Association of Orthopedic Surgeons (AAOS; Rosemont Illinois), annual meeting held last week at the Venetian/Sands EXPO in Las Vegas.


Read More

MDD's Diagnostics Extra

March 27, 2015
By Omar Ford

AAOS 2015: Bioventus establishes its identity, products in ortho-biologics space

March 27, 2015
By Omar Ford

LAS VEGAS — Three years ago, Smith & Nephew (S&N; London) spun off its biologics unit in partnership with Woodlands Essex to form Bioventus (Durham, North Carolina). Fast forward to today, and Bioventus is maintaining a global presence in the biologics market, with about 500 employees strong, and nearly $240 million dollars in yearly revenue.


Read More

AAOS 2015 Meeting: Depuy reaffirms R&D commitment, introduces new products at AAOS

March 26, 2015
By Omar Ford

LAS VEGAS — Nearly four years ago, Johnson & Johnson (J&J;New Brunswick, New Jersey) revealed its intent to acquire Synthes (Solothurn, Switzerland), a firm that develops surgical devices used to treat fractures and traumatic injuries for $21.3 billion. Synthes, has now been carefully folded into J&J's Depuy (Warsaw, Indiana).


Read More

AAOS 2015 Annual Meeting: AAOS panel talks bridging the gap in technological advances in healthcare

March 25, 2015
By Omar Ford

Teleflex hoping Percuvance paves way for category of percutaneous surgery

March 24, 2015
By Omar Ford
Previous 1 2 … 62 63 64 65 66 67 68 69 70 … 227 228 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 8, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 5, 2026
  • Rendering of a key measles protein targeted by neutralizing human antibodies

    First measles treatment advances as vaccination rates drop

    BioWorld
    Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
  • Close up of bow of cruise ship

    Hantavirus is ‘sentinel’ more than acute pandemic threat

    BioWorld
    News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
  • The epidermal growth factor receptor in the inactive (left) and active (right) form.

    Cytospire raises £61M series A to target EGFR in solid tumors

    BioWorld
    Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing